[1] |
Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis, 2010, 50(1): 49-55. doi:10.1086/648675.
doi: 10.1086/648675
pmid: 19947856
|
[2] |
Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med, 2003, 138(2): 135-142. doi:10.7326/0003-4819-138-2-200301210-00015.
doi: 10.7326/0003-4819-138-2-200301210-00015
pmid: 12529096
|
[3] |
Yang C, Lei H, Wang D, et al. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China. Jpn J Infect Dis, 2012, 65(3): 240-242. doi:10.7883/yoken.65.240.
doi: 10.7883/yoken.65.240
URL
|
[4] |
黄海荣, 于霞, 姜广路, 等. 利奈唑胺治疗耐多药结核病的初步评价. 中国防痨杂志, 2011, 33(5): 275-279.
|
[5] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[6] |
唐神结, 肖和平. 利奈唑胺抗结核作用的研究及其最新进展. 中华临床医师杂志(电子版), 2010, 4(1): 63-66. doi:10.3969/j.issn.1674-0785.2010.01.013.
doi: 10.3969/j.issn.1674-0785.2010.01.013
|
[7] |
Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents, 2013, 41(6): 586-589. doi:10.1016/j.ijantimicag.2013.02.020.
doi: 10.1016/j.ijantimicag.2013.02.020
URL
|
[8] |
Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother, 2016, 22(8): 536-542. doi:10.1016/j.jiac.2016.05.003.
doi: 10.1016/j.jiac.2016.05.003
pmid: 27321773
|
[9] |
Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother, 2012, 67(8): 2034-2042. doi:10.1093/jac/dks153.
doi: 10.1093/jac/dks153
pmid: 22553142
|
[10] |
Ballesteros García MDM, Orós Milián ME, Díaz Velázquez E, et al. Myelosupression induced by linezolid: a pediatric case. Arch Argent Pediatr, 2017, 115(6): e420-e423. doi:10.5546/aap.2017.e420.
doi: 10.5546/aap.2017.e420
|
[11] |
Cazavet J, Bounes FV, Ruiz S, et al. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis, 2020, 39(3): 527-538. doi:10.1007/s10096-019-03754-1.
doi: 10.1007/s10096-019-03754-1
URL
|
[12] |
Kaya Kılıç E, Bulut C, Sönmezer MÇ, et al. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination. J Infect Dev Ctries, 2019, 13(10): 886-891. doi:10.3855/jidc.10859.
doi: 10.3855/jidc.10859
URL
|
[13] |
Tajima M, Kato Y, Matsumoto J, et al. Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2. Biol Pharm Bull, 2016, 39(11): 1846-1851. doi:10.1248/bpb.b16-00427.
doi: 10.1248/bpb.b16-00427
pmid: 27803456
|
[14] |
Wang TL, Guo DH, Bai Y, et al. Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress. Clin Drug Investig, 2016, 36(1): 67-75. doi:10.1007/s40261-015-0352-0.
doi: 10.1007/s40261-015-0352-0
URL
|
[15] |
陈璋璋, 吕迁洲. 利奈唑胺相关血小板减少的危险因素分析. 药物不良反应杂志, 2012, 14(4): 218-223.
|
[16] |
王海静, 王盈盈, 许巧巧, 等. 利奈唑胺致血红蛋白减少的相关危险因素. 中国临床药学杂志, 2020, 29(5): 355-359. doi:10.19577/j.1007-4406.2020.05.009.
doi: 10.19577/j.1007-4406.2020.05.009
|
[17] |
中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019, 42(5): 343-356. doi:10.3760/cma.j.issn.1001-0939.2019.05.007.
doi: 10.3760/cma.j.issn.1001-0939.2019.05.007
|
[18] |
Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob, 2016, 15(1): 41. doi:10.1186/s12941-016-0156-y.
doi: 10.1186/s12941-016-0156-y
URL
|
[19] |
Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J, 2012, 40(6): 1430-1442. doi:10.1183/09031936.00022912.
doi: 10.1183/09031936.00022912
pmid: 22496332
|
[20] |
Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J, 2014, 45(1): 161-170. doi:10.1183/09031936.00035114.
doi: 10.1183/09031936.00035114
URL
|
[21] |
Wasserman S, Brust JCM, Abdelwahab MT, et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother, 2022, 77(4): 1146-1154. doi:10.1093/jac/dkac019.
doi: 10.1093/jac/dkac019
pmid: 35134182
|
[22] |
Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect develo-pment of linezolid-induced thrombocytopenia. J Antimicrob Chemother, 2013, 68(9): 2128-2133. doi:10.1093/jac/dkt133.
doi: 10.1093/jac/dkt133
pmid: 23625638
|
[23] |
Song T, Lee M, Jeon HS, et al. Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resis-tant Tuberculosis. EBioMedicine, 2015, 2(11): 1627-1633. doi:10.1016/j.ebiom.2015.09.051.
doi: 10.1016/j.ebiom.2015.09.051
URL
|
[24] |
Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother, 2014, 58(4): 2334-2343. doi:10.1128/AAC.01885-13.
doi: 10.1128/AAC.01885-13
pmid: 24514086
|
[25] |
Dong HY, Xie J, Chen LH, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis, 2014, 33(6): 1029-1035. doi:10.1007/s10096-013-2041-3.
doi: 10.1007/s10096-013-2041-3
URL
|
[26] |
Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis, 2011, 44(1): 60-64. doi:10.3109/00365548.2011.608712.
doi: 10.3109/00365548.2011.608712
URL
|
[27] |
Green S, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA, 2001, 285(10): 1291. doi:10.1001/jama.285.10.1291.
doi: 10.1001/jama.285.10.1291
|
[28] |
Natsumoto B, Yokota K, Omata F, et al. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection, 2014, 42(6): 1007-1012. doi:10.1007/s15010-014-0674-5.
doi: 10.1007/s15010-014-0674-5
pmid: 25119433
|
[29] |
Niwa T, Watanabe T, Suzuki A, et al. Reduction of linezolida-ssociated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight. Diagn Microbiol Infect Dis, 2014, 79(1): 93-97. doi:10.1016/j.diagmicrobio.2014.01.012.
doi: 10.1016/j.diagmicrobio.2014.01.012
URL
|
[30] |
朱熙, 刘丽萍, 胡伟, 等. 利奈唑胺致血液系统不良反应的回顾性研究. 医药导报, 2017, 36(5): 579-583. doi:10.3870/j.issn.1004-0781.2017.05.027.
doi: 10.3870/j.issn.1004-0781.2017.05.027
|
[31] |
Chen C, Guo DH, Cao X, et al. Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp, 2012, 73(6): 195-206. doi:10.1016/j.curtheres.2012.07.002.
doi: 10.1016/j.curtheres.2012.07.002
URL
|
[32] |
曹伟, 卢志品, 余剑华. 利奈唑胺是否需要血药浓度监测? 中国新药与临床杂志, 2016, 35(10): 690-694. doi:10.14109/j.cnki.xyylc.2015.10.002.
doi: 10.14109/j.cnki.xyylc.2015.10.002
|
[33] |
叶雪梅, 陈裕. 利奈唑胺血药浓度与血液毒性相关性的回顾性分析. 药物流行病学杂志, 2020, 29(6): 391-394. doi:10.19960/j.cnki.issn1005-0698.2020.06.004.
doi: 10.19960/j.cnki.issn1005-0698.2020.06.004
|